Esperion to Report Second Quarter 2024 Financial Results on August 12
Esperion (NASDAQ: ESPR) has announced it will report its second quarter 2024 financial results on Monday, August 12, 2024, before the market opens. Following the release, the company will host a webcast at 8:00 a.m. ET to discuss the financial results and provide business updates. Investors can pre-register for the conference call to obtain dial-in information, and a live audio webcast will be accessible on Esperion's website. The webcast replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is focused on discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases. The company aims to help patients with high cholesterol reach their LDL-cholesterol reduction goals.
Esperion (NASDAQ: ESPR) ha annunciato che riporterà i suoi risultati finanziari del secondo trimestre 2024 il lunedì 12 agosto 2024, prima dell'apertura del mercato. Dopo il rilascio, l'azienda ospiterà un webcast alle 8:00 a.m. ET per discutere i risultati finanziari e fornire aggiornamenti aziendali. Gli investitori possono pre-registrarsi per la teleconferenza per ottenere le informazioni di accesso, e un webcast audio dal vivo sarà accessibile sul sito web di Esperion. La registrazione del webcast sarà disponibile circa due ore dopo la chiamata e archiviata per circa 90 giorni.
Esperion è focalizzata alla scoperta, sviluppo e commercializzazione di farmaci innovativi per pazienti con o a rischio di malattie cardiovascolari e cardiometaboliche. L'azienda mira ad aiutare i pazienti con colesterolo alto a raggiungere i loro obiettivi di riduzione del colesterolo LDL.
Esperion (NASDAQ: ESPR) ha anunciado que informará sobre sus resultados financieros del segundo trimestre de 2024 el lunes 12 de agosto de 2024, antes de la apertura del mercado. Después del anuncio, la compañía llevará a cabo un webcast a las 8:00 a.m. ET para discutir los resultados financieros y proporcionar actualizaciones sobre el negocio. Los inversores pueden preinscribirse para la llamada de conferencia y obtener la información de acceso, y un webcast de audio en vivo estará disponible en el sitio web de Esperion. La repetición del webcast estará disponible aproximadamente dos horas después de la llamada y se archivará por unos 90 días.
Esperion se centra en descubrir, desarrollar y comercializar medicamentos innovadores para pacientes con enfermedades cardiovasculares y cardiometabólicas o en riesgo de padecerlas. La compañía tiene como objetivo ayudar a los pacientes con colesterol alto a alcanzar sus metas de reducción del colesterol LDL.
Esperion (NASDAQ: ESPR)는 2024년 2분기 재무 결과를 2024년 8월 12일 월요일에 시장 개장 전에 발표할 것이라고 발표했습니다. 발표 후, 회사는 오전 8:00 ET에 재무 결과에 대해 논의하고 비즈니스 업데이트를 제공하기 위해 웹캐스트를 진행할 예정입니다. 투자자들은 통화 정보를 얻기 위해 컨퍼런스 콜에 미리 등록할 수 있으며, Esperion의 웹사이트에서 라이브 오디오 웹캐스트에 접속할 수 있습니다. 웹캐스트 재생은 통화 약 2시간 후에 제공되며 약 90일 동안 아카이브됩니다.
Esperion은 심혈관 및 심혈관 대사 질환의 위험이 있는 환자를 위한 혁신적인 약물을 발견, 개발 및 상용화하는 데 집중하고 있습니다. 이 회사는 고콜레스테롤 환자가 LDL 콜레스테롤 감소 목표를 달성할 수 있도록 돕는 것을 목표로 하고 있습니다.
Esperion (NASDAQ: ESPR) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 le lundi 12 août 2024, avant l'ouverture des marchés. Suite à la publication, la société organisera un webcast à 8h00 ET pour discuter des résultats financiers et fournir des mises à jour commerciales. Les investisseurs peuvent s'inscrire à l'avance pour la conférence afin d'obtenir les informations d'appel, et un webcast audio en direct sera accessible sur le site web d'Esperion. La rediffusion du webcast sera disponible environ deux heures après l'appel et sera archivée pendant environ 90 jours.
Esperion se concentre sur la découverte, le développement et la commercialisation de médicaments innovants pour les patients présentant ou à risque de maladies cardiovasculaires et cardiométaboliques. L'entreprise vise à aider les patients ayant un taux de cholestérol élevé à atteindre leurs objectifs de réduction du cholestérol LDL.
Esperion (NASDAQ: ESPR) hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Montag, den 12. August 2024, vor Marktöffnung bekanntgeben wird. Nach der Veröffentlichung wird das Unternehmen um 8:00 Uhr ET ein Webcast abhalten, um die Finanzergebnisse zu diskutieren und Unternehmensupdates zu geben. Investoren können sich für die Konferenzschaltung vorab registrieren, um die Einwahlinformationen zu erhalten, und ein Live-Audio-Webcast wird auf der Website von Esperion verfügbar sein. Die Aufzeichnung des Webcasts wird etwa zwei Stunden nach dem Anruf verfügbar sein und etwa 90 Tage lang archiviert.
Esperion konzentriert sich auf die Entdeckung, Entwicklung und Kommerzialisierung innovativer Medikamente für Patienten mit oder gefährdet durch kardiovaskuläre und kardiometabolische Erkrankungen. Das Unternehmen hat sich zum Ziel gesetzt, Patienten mit hohem Cholesterinspiegel dabei zu helfen, ihre LDL-Cholesterin-Reduktionsziele zu erreichen.
- Timely reporting of quarterly financial results
- Proactive investor communication through webcast and conference call
- Focus on innovative medicines for cardiovascular and cardiometabolic diseases
- None.
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) report its Q2 2024 financial results?
What time is Esperion's (ESPR) Q2 2024 earnings webcast scheduled for?
How can investors access Esperion's (ESPR) Q2 2024 earnings call?
What is Esperion's (ESPR) main focus in drug development?
